My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 485 / DOI: 10.3332/ecancer.2014.485

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Keywords: Drug repurposing, cimetidine, immunostimulant, ReDO project

Loading Article Metrics ... Please wait

Related articles

Research: Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis

Abstract | Full Article | PDF Published: 01 Dec 2016 / DOI: 10.3332/ecancer.2016.699

Review: The current status of prophylactic femoral intramedullary nailing for metastatic cancer

Abstract | Full Article | PDF Published: 01 Dec 2016 / DOI: 10.3332/ecancer.2016.698

Case Report: Radiation-induced breast angiosarcoma: a case report

Abstract | Full Article | PDF | Spanish Published: 29 Nov 2016 / DOI: 10.3332/ecancer.2016.697

Case Report: Solitary thyroid metastasis from colon cancer: a rare case report

Abstract | Full Article | PDF Published: 24 Nov 2016 / DOI: 10.3332/ecancer.2016.696

Case Report: Hepatic metastasis of thymoma: case report and immunohistochemical study

Abstract | Full Article | PDF | Spanish Published: 22 Nov 2016 / DOI: 10.3332/ecancer.2016.693



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence